Skip to content
Original
mp.weixin.qq.com·· 16 hours agoPickScore82

Chinese and Japanese Experts Discuss Evidence-Based Treatment and Whole-Course Management of Elderly Advanced NSCLC

In brief

Chinese and Japanese experts met online on October 15, 2026, to discuss assessment, stratified treatment, and whole-course management of elderly advanced NSCLC. Citing studies including NEJ057, they noted that elderly PD-L1-positive patients had similar PFS and OS with ICI plus chemotherapy versus ICI monotherapy, but the combination group had more grade 3 or higher immune-related adverse events. The Chinese side presented the 9 recommendations of the 2026 Expert Consensus on Treatment of Elderly Advanced Lung Cancer, plus practical experience of initiating CGA after a G-8 score of 14 or below and embedding it in MDT and follow-up.

Why it matters

The article uses the China-Japan expert discussion to juxtapose evidence and practice gaps in geriatric assessment, treatment stratification, and whole-course management for comparison.

Source: mp.weixin.qq.com · mp.weixin.qq.com

#Review & opinion#Oncology#Immunotherapy#Biomarkers
CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.